- Global Blood Therapeutics (NASDAQ:GBT) intends to submit a marketing application in Europe seeking approval to use Oxbryta (voxelotor) to treat hemolytic anemia in patients at least 12 years old with sickle cell disease (SCD). It expects to complete the filing by mid-2021.
- Voxelotor inhibits hemoglobin polymerization, the root causes of the sickling and destruction of red blood cells in SCD.
- The FDA approved Oxbryta in November 2019 for SCD.